


## PROTAC HDAC6 degrader 1

Cat. No.:	HY-152133
CAS No.:	2785404-76-2
Molecular Formula:	C <sub>37</sub> H <sub>46</sub> N <sub>6</sub> O <sub>10</sub>
Molecular Weight:	734.8
Target:	PROTACs; HDAC; Apoptosis
Pathway:	PROTAC; Cell Cycle/DNA Damage; Epigenetics; Apoptosis
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.



### BIOLOGICAL ACTIVITY

<b>Description</b>	PROTAC HDAC6 degrader (Compound A6) is a potent and selective PROTAC HDAC6 degrader with a DC <sub>50</sub> of 3.5 nM. PROTAC HDAC6 degrader shows promising antiproliferative activity via inducing apoptosis in myeloid leukemia cell lines <sup>[1]</sup> .																		
<b>IC<sub>50</sub> &amp; Target</b>	HDAC6 3.5 nM (DC <sub>50</sub> )	HDAC6 4.86 nM (IC <sub>50</sub> )	HDAC1 0.1 μM (IC <sub>50</sub> )																
<b>In Vitro</b>	<p>PROTAC HDAC6 degrader (Compound A6) (0.1-10 μM; 6 h) does not degrade HDAC1 but displays inhibitory activity toward HDAC1. PROTAC HDAC6 degrader demonstrates potent HDAC6 degradation as well as hyperacetylation of α-tubulin in U266 and HL-60 cells, confirming that the activity is not restricted to leukemia cell lines<sup>[1]</sup>.</p> <p>PROTAC HDAC6 degrader (0.5-50 μM) inhibits leukemia cells viability with log IC<sub>50</sub> values of 1.2-1.7 μM<sup>[1]</sup>.</p> <p>PROTAC HDAC6 degrader (8-24 μM; 48 h) induces MOLM13 cell apoptosis and arrests cell cycle at sub-G1 phase<sup>[1]</sup>.</p> <p>MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p> <p>Western Blot Analysis<sup>[1]</sup></p> <table border="1"> <tr> <td>Cell Line:</td> <td>HL-60 cells</td> </tr> <tr> <td>Concentration:</td> <td>100 nM, 1 μM, 10 μM</td> </tr> <tr> <td>Incubation Time:</td> <td>6 h</td> </tr> <tr> <td>Result:</td> <td>Degraded HDAC6 but not HDAC1. Induced hyperacetylation of α-tubulin and caused hyperacetylation of histone H3.</td> </tr> </table> <p>Cell Viability Assay<sup>[1]</sup></p> <table border="1"> <tr> <td>Cell Line:</td> <td>Acute myeloid leukemia or AML (HL-60, Kasumi, THP-1, HL-60, SKNO1, and MOLM13) and B-cell acute lymphoblastic leukemia or B-ALL (REH and 697)</td> </tr> <tr> <td>Concentration:</td> <td>0.5-50 μM</td> </tr> <tr> <td>Incubation Time:</td> <td>72 h</td> </tr> <tr> <td>Result:</td> <td>Inhibited cell viability with log IC<sub>50</sub> values of 1.2-1.7 μM.</td> </tr> </table> <p>Apoptosis Analysis<sup>[1]</sup></p>			Cell Line:	HL-60 cells	Concentration:	100 nM, 1 μM, 10 μM	Incubation Time:	6 h	Result:	Degraded HDAC6 but not HDAC1. Induced hyperacetylation of α-tubulin and caused hyperacetylation of histone H3.	Cell Line:	Acute myeloid leukemia or AML (HL-60, Kasumi, THP-1, HL-60, SKNO1, and MOLM13) and B-cell acute lymphoblastic leukemia or B-ALL (REH and 697)	Concentration:	0.5-50 μM	Incubation Time:	72 h	Result:	Inhibited cell viability with log IC <sub>50</sub> values of 1.2-1.7 μM.
Cell Line:	HL-60 cells																		
Concentration:	100 nM, 1 μM, 10 μM																		
Incubation Time:	6 h																		
Result:	Degraded HDAC6 but not HDAC1. Induced hyperacetylation of α-tubulin and caused hyperacetylation of histone H3.																		
Cell Line:	Acute myeloid leukemia or AML (HL-60, Kasumi, THP-1, HL-60, SKNO1, and MOLM13) and B-cell acute lymphoblastic leukemia or B-ALL (REH and 697)																		
Concentration:	0.5-50 μM																		
Incubation Time:	72 h																		
Result:	Inhibited cell viability with log IC <sub>50</sub> values of 1.2-1.7 μM.																		

Cell Line:	MOLM13
Concentration:	8, 16 and 24 $\mu$ M
Incubation Time:	48 h
Result:	Induced caspase 3/7-dependent apoptosis in dose-dependent fashion.
Cell Cycle Analysis <sup>[1]</sup>	
Cell Line:	MOLM13
Concentration:	8, 16 and 24 $\mu$ M
Incubation Time:	48 h
Result:	Induced a dose-dependent increase in the sub-G1 fraction with a concomitant reduction of cell population in G2/M phase.

## REFERENCES

[1]. Sinatra L, et al. Solid-Phase Synthesis of Cereblon-Recruiting Selective Histone Deacetylase 6 Degraders (HDAC6 PROTACs) with Antileukemic Activity. *J Med Chem.* 2022 Dec 22;65(24):16860-16878.

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA